Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Certificates of analysis are available upon request.
Jun 2011;11(6):661-669
4.3 The potential of peptide-based redevelopment of dendritic cell vaccines After considerable endeavors, sipuleucel-T stands alone as the immunotherapeutic agent that has yielded a significant survival benefit in a randomized Phase 3 clinical trial (Kantoff et al., 2010)
Multinucleated myofiber apoptosis is distinct from mononucleated cell apoptosis, which results in the complete loss of the cell's nucleus, but does not always lead to cell death
US$ 22.88
US$ 23.10
US$ 26.03
US$ 21.78
US$ 29.50
